» Articles » PMID: 25192974

Impact of Conjugation Chemistry on the Immunogenicity of S. Typhimurium Conjugate Vaccines

Overview
Journal Vaccine
Date 2014 Sep 7
PMID 25192974
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Salmonella Typhimurium is major cause of invasive nontyphoidal Salmonella disease in Africa. Conjugation of S. Typhimurium O-antigen to an appropriate carrier protein constitutes a possible strategy for the development of a vaccine against this disease, for which no vaccines are currently available. The conjugation chemistry used is one of the parameters that can affect the immunogenicity of glycoconjugate vaccines. Herein different glycoconjugates were synthesized to investigate the impact of this variable on the immunogenicity of S. Typhimurium conjugate vaccines in mice, all with CRM₁₉₇ as carrier protein. Random derivatization along the O-antigen chain was compared with site-directed activation of the terminal KDO sugar residue of the core oligosaccharide. In particular, two different random approaches were used, based on the oxidation of the polysaccharide, which differently impact the structure and conformation of the O-antigen chain. For the selective conjugation methods, linkers of two different lengths were compared. When tested in mice, all conjugates induced anti-O-antigen IgG antibodies with serum bactericidal activity. Similar anti-O-antigen antibody levels were elicited independent of the chemistry used and a higher degree of saccharide derivatization did not impact negatively on the anti-O-antigen IgG response. Bactericidal activity of serum antibodies induced by selective conjugates was similar independent of the length of the spacer used. Random conjugates elicited antibodies with greater bactericidal activity than selective ones, and an inverse correlation was found between degree of O-antigen modification and antibody functional activity.

Citing Articles

Design of a Glycoconjugate Vaccine Against Paratyphi A.

Alfini R, Carducci M, Massai L, De Simone D, Mariti M, Rossi O Vaccines (Basel). 2024; 12(11).

PMID: 39591175 PMC: 11599127. DOI: 10.3390/vaccines12111272.


Comparison of GMMA and glycoconjugate four-component formulations in animals.

Di Benedetto R, Mancini F, Caradonna V, Aruta M, Giannelli C, Rossi O Front Mol Biosci. 2023; 10:1284515.

PMID: 38046812 PMC: 10690372. DOI: 10.3389/fmolb.2023.1284515.


Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.

Micoli F, Stefanetti G, MacLennan C Front Mol Biosci. 2023; 10:1201693.

PMID: 37261327 PMC: 10227950. DOI: 10.3389/fmolb.2023.1201693.


Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1.

Ou L, Gulla K, Biju A, Biner D, Bylund T, Changela A Vaccines (Basel). 2022; 10(11).

PMID: 36423012 PMC: 9698951. DOI: 10.3390/vaccines10111916.


Impact and Control of Sugar Size in Glycoconjugate Vaccines.

Stefanetti G, MacLennan C, Micoli F Molecules. 2022; 27(19).

PMID: 36234967 PMC: 9572008. DOI: 10.3390/molecules27196432.